A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies

Trial Details

NCT ID
NCT05836896
Phase
PHASE1
Sponsor
Technische Universität Dresden
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
Locations (sample)
  • Dresden, Germany|51.05089,13.73832

Key Eligibility Criteria

  • Male or female patients aged ≥ 18 years
  • Written informed consent of the subject
  • Able and willing to adhere to the trial protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →